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Commentary: Death in the era of potent
antiretroviral therapy: shifting causes, 
new challenges
Marcel Zwahlen1* and Jens D Lundgren2
Several studies have shown that the introduction of highly
active antiretroviral therapies (HAART) has lead to a substantial
reduction in HIV-associated mortality.1–4 This in turn has
resulted in a notable shift in causes of death among adults who
died with or due to HIV infection.5–11 In this issue Lewden et al.
present the results of a nation-wide survey of the causes of
death of 964 HIV-infected individuals who died in the year 2000
in 185 wards in France.12
Their study has several strengths. The investigators made
extensive efforts to ascertain all deaths among HIV-infected
individuals cared for in hospitals known to be involved in the
management of HIV infection in France. They visited sites to
check and enhance the completeness and accuracy of the
available information. Finally, they collected an array of
important and detailed information on the deceased HIV-infected
individuals, going far beyond what is available from routine
hospital records or death certificates.
AIDS/HIV infection was attributed to be the underlying cause
of the death in about half the cases, and cancer, cardiovascular
diseases, hepatitis C, and bacterial infections in a third. Of note,
only three quarters of deceased patients had received HAART
treatment prior to death and the excess of infections among the
causes of death of HIV-infected people compared with the
background population is remarkable. Most of these infections
are preventable by using HAART and effective chemopro-
phylaxis, including Pneumocystis pneumonia and tuberculosis.
One in nine had the HIV infection diagnosed only recently and
a third lived in poor socio-economic conditions. Clearly, HIV-
associated mortality is increasingly affecting individuals with
multiple risk factors, including social deprivation and reduced
access to health services. These important results reinforce the
notion that implementing equitable access to HIV diagnosis and
treatment is not only a challenge for the less developed
countries but also for economically developed societies, many of
whom suffer from substantial health and social disparities.
There are important concerns whether longer duration of
antiretroviral therapy, known to affect various metabolic
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parameters, will result in deregulated glucose metabolism13 and
excess risk of cardiovascular diseases.14 The data of Lewden
et al. underline that this concern has not materialized yet, and
not led to notable shifts in mortality patterns. Independent of
these concerns cigarette smoking and excessive alcohol
consumption is prevalent in many HIV-infected populations and
it is hardly surprising that the mortality risks most prominent in
the general middle-aged population, cancers and cardiovascular
diseases, are also affecting those with HIV infection. Now that
HAART-regimens have considerably improved the life
expectancy in HIV-infected populations in industrialized
countries, efforts to reduce smoking and alcohol consumption
must be a priority in HIV medicine.
Finally, a few words of caution are in order. The study is based
on deaths in 2000, and therefore restricted to a period when the
experience with HAART was still limited. Indeed, the longer-term
consequences of using this effective medication—in terms of its
risk to benefit ratio—in various population settings remain to be
defined. The investigators have undertaken extensive efforts to
collect detailed information on deceased individuals. However,
there is no simple and agreed method of obtaining accurate
information at and after the death of a person. For example,
information from hospital records and on death certificates do not
always agree and no gold standard is available.15,16 Classification
of deaths can also be difficult, for example when faced with
sudden deaths in middle-aged patients with a history of
intravenous drug use. More importantly, comparing the
proportion of a certain cause of death across groups of patients
cannot substitute analyses of absolute risks derived from
appropriate numerator and denominator data.17 Here, prospective
cohort studies of HIV-infected individuals can make important
contributions, particularly when several studies are analysed
collaboratively in order to increase statistical power.3,4,14 It is,
however, essential for such studies to implement standardized
procedures for the ascertainment and classification of causes of
deaths. This is not the case at present, but should be introduced in
the near future thanks to the efforts of a cross-cohort working
group which, co-ordinated by the Copenhagen HIV Programme
(www.cphiv.dk), is developing the CoDe (Coding Death in HIV)
standards. These efforts, in combination with careful cross-
sectional studies such as the one done by Lewden et al. will in the
future inform the medical and wider community about the long-
term outcomes of treated HIV infection.
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